Aska Pharmaceutical Co Sustainability Profile
Aska Pharmaceutical Co., Ltd., commonly referred to as Aska Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan (JP). Established in 1941, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of prescription pharmaceuticals and over-the-counter products. With a strong operational presence in Asia and beyond, Aska Pharma focuses on therapeutic areas such as cardiovascular, oncology, and infectious diseases. Their core offerings include unique formulations and advanced drug delivery systems that set them apart in a competitive market. Recognised for their commitment to quality and research, Aska Pharmaceutical has achieved notable milestones, including strategic partnerships and a robust pipeline of new drugs. Their dedication to improving patient outcomes solidifies their position as a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Aska Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aska Pharmaceutical Co's score of 33 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aska Pharmaceutical Co's reported carbon emissions
In 2023, Aska Pharmaceutical Co reported total carbon emissions of approximately 41,812,000 kg CO2e. This figure includes Scope 1 emissions of about 12,895,000 kg CO2e, Scope 2 emissions of around 12,110,000 kg CO2e, and Scope 3 emissions totalling approximately 16,807,000 kg CO2e. The Scope 3 emissions breakdown reveals significant contributions from capital goods (about 5,263,000 kg CO2e), purchased goods and services (approximately 6,233,000 kg CO2e), and employee commuting (around 977,000 kg CO2e). Comparatively, the total emissions for 2022 were reported at approximately 26,727,000 kg CO2e for Scope 1 and 2 combined, indicating a substantial increase in emissions in 2023. The previous years also show a trend of decreasing emissions, with 2021 at about 27,594,000 kg CO2e and 2020 at approximately 29,074,000 kg CO2e. Aska Pharmaceutical has not set specific reduction targets or climate pledges, and there are no reported initiatives under the Science Based Targets initiative (SBTi). The emissions data is sourced directly from Aska Pharmaceutical Holdings Co., Ltd., with no cascaded data from parent companies. Overall, Aska Pharmaceutical Co's emissions profile highlights the need for enhanced climate commitments and reduction strategies to address the significant carbon footprint associated with its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 00,000,000 |
| Scope 2 | - | - | - | - | - | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
How Carbon Intensive is Aska Pharmaceutical Co's Industry?
How Carbon Intensive is Aska Pharmaceutical Co's Location?
Aska Pharmaceutical Co's Scope 3 Categories Breakdown
A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 40% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 37% of Scope 3 emissions.
Top Scope 3 Categories
Aska Pharmaceutical Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aska Pharmaceutical Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
